Assessing Ocular Therapeutix (OCUL) Valuation After Recent Share Price Weakness

Simply Wall St.06-08 09:20

AdvertisementOcular Therapeutix stock moves Ocular Therapeutix (OCUL) has been drawing attention after a stretch of weak share performance, with the stock down 6.3% on the day and declining over the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2641177992?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","is_english":true,"pubTime":"2026-06-08 09:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2641177992","market":"hk","top_or_hot":-1,"title":"Assessing Ocular Therapeutix (OCUL) Valuation After Recent Share Price Weakness","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementOcular Therapeutix stock moves Ocular Therapeutix (OCUL) has been drawing attention after a stretch of weak share performance, with the stock down 6.3% on the day and declining over the ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ocul/ocular-therapeutix/news/assessing-ocular-therapeutix-ocul-valuation-after-recent-sha-3\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Ocular Therapeutix (OCUL) Valuation After Recent Share Price Weakness</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Ocular Therapeutix (OCUL) Valuation After Recent Share Price Weakness\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-08 09:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ocul/ocular-therapeutix/news/assessing-ocular-therapeutix-ocul-valuation-after-recent-sha-3><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementOcular Therapeutix stock moves Ocular Therapeutix (OCUL) has been drawing attention after a stretch of weak share performance, with the stock down 6.3% on the day and declining over the ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ocul/ocular-therapeutix/news/assessing-ocular-therapeutix-ocul-valuation-after-recent-sha-3\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OCUL","symbol_name":"Ocular Therapeutix","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ocul/ocular-therapeutix/news/assessing-ocular-therapeutix-ocul-valuation-after-recent-sha-3","article_id":"2641177992","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ocul/ocular-therapeutix/news/assessing-ocular-therapeutix-ocul-valuation-after-recent-sha-3","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2641177992","pubTimestamp":1780881646,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Ocular Therapeutix stock moves\nOcular Therapeutix (OCUL) has been drawing attention after a stretch of weak share performance, with the stock down 6.3% on the day and declining over the past week, month, and past 3 months.\nSee our latest analysis for Ocular Therapeutix.\nThat weak one day share price move sits on top of a fading trend, with the 30 day share price return down 14.51%, the year to date share price return down 30.20%, and the 1 year total shareholder return down 8.54%, even though...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"OCUL":"Ocular Therapeutix","BK4007":"制药"},"translate_title":"近期股价疲软后评估Ocular Therapeutix(OCUL)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OCUL":1.5},"content_text":"AdvertisementOcular Therapeutix stock moves Ocular Therapeutix (OCUL) has been drawing attention after a stretch of weak share performance, with the stock down 6.3% on the day and declining over the past week, month, and past 3 months. See our latest analysis for Ocular Therapeutix. That weak one day share price move sits on top of a fading trend, with the 30 day share price return down 14.51%, the year to date share price return down 30.20%, and the 1 year total shareholder return down 8.54%, even though the 3 year total shareholder return is positive at 11.04%. If you are weighing OCUL against other healthcare ideas, this could be a good moment to widen the net and scan for 39 healthcare AI stocks With OCUL trading at $8.25 and carrying a value score of 2, yet sitting at a large discount to a US$26 price target and an intrinsic discount of 91.08%, is there a genuine opportunity here, or is the market already pricing in future growth? Most Popular Narrative: 68.3% Undervalued At $8.25 a share versus a narrative fair value of $26, the gap on Ocular Therapeutix is wide, and the current focus sits squarely on its retinal franchise.  The anticipated approval of AXPAXLI, potentially the first wet AMD product with a superiority label and longer dosing intervals (every 6 to 12 months), may allow Ocular Therapeutix to capture significant market share in a rapidly growing population of elderly patients with retinal disease, unlocking large revenue growth opportunities as the global prevalence of ophthalmic disorders increases.  Read the complete narrative. Curious what underpins that $26 figure? The narrative leans on rapid revenue expansion, a sharp swing in profit margins and a future earnings multiple more often seen in high growth sectors. Result: Fair Value of $26 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this upbeat story leans heavily on AXPAXLI. Any clinical or regulatory setback, or slower than expected physician adoption, could quickly challenge that $26 narrative. Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page. Another View: Rich Sales Multiple Raises the Bar That $26 fair value from the narrative leans heavily on future cash flows, but today the market is already paying a very high price for OCUL's current sales. The stock trades on a P/S of 34.7x, compared with 5.8x for the US pharmaceuticals industry and 5.5x for peers, while the fair ratio is just 0.1x. For investors, the question is whether future growth can close such a wide gap or if the multiple itself becomes the main risk. Before relying on any single approach, it can help to see what the numbers imply when this sales ratio is pushed back toward a fair ratio in our valuation work. You can review this in more detail in the See what the numbers say about this price — find out in our valuation breakdown.. NasdaqGM:OCUL P/S Ratio as at Jun 2026Next Steps With sentiment clearly mixed after all this, it makes sense to move fast, review the full picture yourself and weigh both sides using the 2 key rewards and 2 important warning signs. Looking for more investment ideas? OCUL may be on your radar, but the market is full of other opportunities, so do not miss the chance to line up your next moves.  Spot potential value plays early by scanning 49 high quality undervalued stocks before other investors pay attention. Prioritise resilience and sleep easier at night by focusing on 61 resilient stocks with low risk scores that score well on stability. Act on underfollowed opportunities by running the screener containing 21 high quality undiscovered gems and seeing which solid fundamentals the crowd is overlooking.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2641177992","isCrawlerRequest":true}